It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start?
The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage.
Doctors also expect some patients will hesitate to take Leqembi due to its limited impact and potential side effects. They say it will take years to learn how best to deploy the drug and that work must be done to improve diagnosis.
“This is the start of a very exciting journey,” said Dr. Ambar Kulshreshtha, a suburban Atlanta family physician focused on dementia patients.
More than 6 million Americans, and millions more worldwide, have Alzheimer’s disease, the most common cause of dementia. There’s no cure, but Leqembi clears a sticky brain protein called amyloid that’s a key indicator of Alzheimer’s.
Studies showed that it can delay the progression of the disease by a few months when given to people with mild symptoms. Some experts say the delay may be too subtle for patients to notice.
Related articles
China's archaeological site parks register strong revenue growth
This photo shows peonies at the National Archaeological Site Park of Sui-Tang Luoyang City in Luoyan2024-04-30China Focus: China Holds National Commemoration for Nanjing Massacre Victims
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-04-30Tibet's Rural Residents Enjoy Improved Livelihood over Past Decade
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-04-307th Sanya Int'l Cultural Industry Fair Opens in Sanya, S China's Hainan
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-04-30Overseas Chinese history museum opens new branch in S. China
The Overseas Chinese History Museum of China has opened a new branch in the city of Chaozhou in sout2024-04-30China and Japan to Meet in Women's Final at Table Tennis Team Worlds
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-04-30
atest comment